← All stocks

Tarsus Pharmaceuticals, Inc.

TARS Net selling
CIK 0001819790 #1728 in the set updated 22 Sep 2026
Bought (120 mo)
$16.53M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$66.87M
$18.07M on a plan · $1.15M straight out of an exercise
Sold at will
$47.66M
191 of 260 sales
Net
−$50.35M
−$31.13M against sales at will

By person

24 insiders · 274 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Azamian Bobak R.
President/CEO and Board Chair
$15.04M (88) scheduled
−$15.04M
1,709,403
3.90%
$136.77M
−19.0%
RTW INVESTMENTS, LP entity
10% owner
$13.49M (1)
−$13.49M
2,013,601
4.59%
$161.11M
−18.3%
Vivo Capital IX, LLC entity
10% owner
$4.00M (1)
$14.46M (10)
−$10.46M
8,701,367
19.83%
$696.20M
+39.6%
LINK WILLIAM J PHD
Director
$6.94M (16) scheduled
−$6.94M
1,206,788
2.75%
$96.56M
−3.2%
Frazier Life Sciences IX, L.P.
10% owner
$5.00M (1)
+$5.00M
1,917,157
4.37%
$153.39M
Whitfield Dianne C.
Chief Human Resources Officer
$3.36M (22) scheduled
−$3.36M
35,028
0.0798%
$2.80M
+1,675%
Horowitz Limited Partnership VIII entity
10% owner
$2.95M (2)
+$2.95M
1,987,105
4.53%
$158.99M
Mottiwala Aziz
Chief Commercial Officer
$2.87M (25)
−$2.87M
61,480
0.1401%
$4.92M
+8.3%
Tester Jason E.
Director
$2.75M (2)
+$2.75M
1,949,331
4.44%
$155.97M
Neervannan Seshadri
Chief Operating Officer
$2.54M (16)
−$2.54M
79,482
0.1811%
$6.36M
+41.9%
Farrow Jeffrey S
See Remarks
$2.33M (9)
−$2.33M
56,801
0.1294%
$4.54M
+8,014%
Lin Elizabeth Yeu
Chief Medical Officer
$456.31K (3)
$2.40M (12) scheduled
−$1.95M
32,043
0.0730%
$2.56M
+102.0%
Wahl Bryan
General Counsel
$1.67M (17)
−$1.67M
63,959
0.1457%
$5.12M
+537.0%
Greenstein Leonard M.
Chief Financial Officer
$708.04K (16)
−$708.04K
26,785
0.0610%
$2.14M
−61.3%
Ackermann Michael
Director
$1.35M (1)
$752.39K (16)
+$597.61K
1,308,273
2.98%
$104.67M
+12.2%
Goodrich Katherine
Director
$183.38K (1) scheduled
−$183.38K
2,233
0.0051%
$178.66K
Trevejo Jose M.
CHIEF MEDICAL OFFICER
$113.02K (8) scheduled
−$113.02K
2,251
0.0051%
$180.10K
+40.3%
Goldberg Andrew D.
Director
$18.96K (1)
+$18.96K
19,654
0.0448%
$1.57M
Holdbrook Mark J.
V.P., Clinical Affairs
$7.50K (3)
−$7.50K
3,191
0.0073%
$255.31K
+187.2%
YARNO WENDY L
Director
16,956
0.0386%
$1.36M
CHAUDHURI BHASKAR
Director
11,654
0.0266%
$932.44K
PYOTT DAVID E I
Director
10,958
0.0250%
$876.75K
+16.9%
Morrison Scott W
Director
7,638
0.0174%
$611.12K
Crane Rosemary A
Director
5,350
0.0122%
$428.05K
Insider
Date
Role
Action
Shares
Price
Amount
Goldberg Andrew D.
15 Dec 2023
Director
Buy
1,000
$18.96
$18.96K
Lin Elizabeth Yeu
15 Aug 2023
Director
Buy indirect
9,506
$16.80
$159.70K
Lin Elizabeth Yeu
14 Sep 2022
Director
Buy indirect
6,360
$16.29
$103.60K
Lin Elizabeth Yeu
14 Sep 2022
Director
Buy indirect
12,040
$16.03
$193.00K
Ackermann Michael
5 May 2022
Director
Buy indirect
100,000
$13.50
$1.35M
Showing 250 of 274 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 303
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 8
Sales on a Rule 10b5-1 plan 64
Sales straight out of an exercise 5
Sales at will 191
Transactions with no price 0
Shares from compensation/vesting 11,493,487
Sales filed before the plan box existed 99
History held since 20 Oct 2020